NEW YORK (GenomeWeb News) – Qiagen has acquired CLC Bio, a bioinformatics software company based in Aarhus, Denmark.
The news was first reported on AllSeq's blog. GenomeWeb Daily News independently confirmed the acquisition. A CLC Bio official declined to comment. On deadline, Qiagen did not respond to an e-mail requesting comment.
CLC Bio develops and markets software for analyzing genomic data from next-generation sequencing platforms and traditional Sanger sequencing instruments. Its product portfolio includes tools such as the CLC Genomics Workbench, the CLC Main Workbench, and the CLC Genomics Server.
In April, the company and IBM said they would be offering a turnkey next-generation sequencing data analytics solution that combines their respective products.
Privately held CLC increased its software sales by 30 percent in 2012, it said earlier this year, but declined to provide specifics, as BioInform previously reported.
The acquisition is the second significant buy this year in the bioinformatics space by Qiagen and follows the company's purchase in April of genomic data analysis firm Ingenuity Systems for $105 million. At the time, Qiagen said that new technologies, such as next-generation sequencing, were generating massive amounts of data and being able to interpret the data is "a critical success factor."
The Ingenuity purchase, Qiagen said, will expand and strengthen its own curated database.